Stay updated with breaking news from Alkermes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This study is the first to assess the efficacy of this drug combination in a real-world setting.
Alkermes will present new data on ALKS 2680, an investigational orexin-2 receptor agonist for narcolepsy, at World Sleep Congress.
/PRNewswire/ -- Mural Oncology plc, the publicly-traded oncology company that Alkermes plc (Nasdaq: ALKS) plans to establish in the fourth quarter of 2023...
StockNews.com began coverage on shares of Alkermes (NASDAQ:ALKS – Free Report) in a research note issued to investors on Thursday. The firm issued a strong-buy rating on the stock. ALKS has been the subject of several other reports. Cantor Fitzgerald reiterated an overweight rating on shares of Alkermes in a research report on Monday, July […]
One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks...